ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract (PAEAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03449459
Recruitment Status : Not yet recruiting
First Posted : February 28, 2018
Last Update Posted : February 28, 2018
Sponsor:
Collaborators:
The First Affiliated Hospital of Guangzhou Medical University
Ruijin Hospital
Information provided by (Responsible Party):
Shanghai Zhongshan Hospital

Brief Summary:
The colonization of potential pathogenic bacteria in lower respiratory tract is thought to be accountable for acute exacerbation in subjects with moderate to severe COPD. However, there is no accepted therapy for patients with COPD to remove the colonized bacteria in lower respiratory tract. Therefore, we plan to perform a multi-center, randomized, controlled trial to study the efficacy and safety of oral probiotics, aerosol inhaled amikacin or combined vaccination to decolonize bacteria in lower respiratory tract and prevent acute exacerbation of COPD.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease (COPD) Dietary Supplement: oral probiotics Drug: aerosol inhaled amikacin Biological: combined vaccination Early Phase 1

Detailed Description:

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incomplete reversible airflow limitation, small airway obstruction and alveolar structural damage. About 3 million patients die from COPD every year around the world. The prevalence of COPD in Chinese people over the age of 40 is as high as 12 % and has risen by 50 % in the past nine years.

Acute exacerbation is the leading cause of death in patients with COPD , and accounts for a majority of expenditure of COPD management. The colonization of potential pathogenic bacteria in the lower respiratory tract is an important cause of the acute exacerbation especially in patients with moderate and severe COPD.

Some clinical studies show that aerosol inhaled antibiotics is promising in reducing acute exacerbation, but these exploratory studies have some defects so that they can't back up for the clinical application of aerosol inhaled antibiotics. Amikacin, a kind of aminoglycosides, is sensitive to the common pathogens of acute exacerbation of COPD in China. Therefore it is necessary to carry out a clinical trial to verify its efficacy and safety in pathogen decolonization and prevention of acute exacerbation.

In addition, owing to bacterial resistance and insufficient antibiotics concentration in lower respiratory tract, developing new antibacterial materials is necessary. Oral probiotics is an another way to regulate the bacterial load and inflammatory response in lower respiratory tract, which has been proven to effectively prevent acute exacerbation in cystic fibrosis and childhood asthma. Likewise, airway bacterial burden and inflammation are two main mechanisms of acute exacerbation in COPD. Hence, considering its convenience and safety of oral probiotics, we perform a trial to make clinical evaluation for it.

What's more, influenza and streptococcus pneumoniae vaccines are separately recommended for patients with COPD in the Global Initiative for Chronic Obstructive Pulmonary Disease(GOLD), but there have been no studies on the effects of combined vaccination on bacterial decolonization in lower respiratory tract or on the prevention of acute exacerbation.

Effects of these above methods on the decolonization of potential pathogenic bacteria in lower respiratory tract and the inflammatory reaction are not clear. Therefore, we plan to perform a multi-center, randomized, controlled trial to study the efficacy and safety of oral probiotics, aerosol inhaled amikacin or combined vaccination to decolonize bacteria in lower respiratory tract and prevent acute exacerbation of COPD.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants are equally assigned to four groups in parallel to accept oral probiotics, aerosol inhaled amikacin, combined vaccination or blank control for the duration of the study.
Masking: None (Open Label)
Masking Description: Although this study is unblinded, we will adopt method of allocation concealment to reduce selection bias.
Primary Purpose: Prevention
Official Title: A Randomized, Parallel, Controlled, Exploratory Study: the Efficacy and Safety of Taking Probiotics, Inhaled Antibiotics or Combined Vaccination to Prevent Acute Exacerbation in Subjects With Moderate to Severe COPD and Decolonize Bacteria in Lower Respiratory Tract.
Estimated Study Start Date : July 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: oral probiotics Dietary Supplement: oral probiotics

Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months.

Subjects will take conventional therapy at the same time.


Experimental: aerosol inhaled amikacin Drug: aerosol inhaled amikacin

0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.

In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.

Subjects will take conventional therapy at the same time.


Experimental: combined vaccination Biological: combined vaccination

Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses.

The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events.

Subjects will take conventional therapy at the same time.


No Intervention: conventional therapy (blank control)
According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.



Primary Outcome Measures :
  1. Time to the first COPD exacerbation [ Time Frame: 15 months ]

    COPD exacerbation refers to deterioration of patients' daily symptoms requiring treatment with antibiotics or systemic glucocorticoid therapy.

    First COPD exacerbations starting between first dose and one day after last follow-up are included.



Secondary Outcome Measures :
  1. Colonization of potential pathogenic bacteria in induced sputum [ Time Frame: Baseline, 3 months ]
    Induced sputum represents the specimen from lower respiratory tract and should be processed within six hours after collection. Sputum plugs were separated from contaminating saliva by macroscopic examination using sterile forceps. Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Pseudomonas aeruginosa which are the top four bacteria involved in acute exacerbation of COPD are defined as potential pathogenic bacteria. Using the plate count method, when the colony number of above four bacteria is over 100 cfu/ml,we define this bacteria as colonized bacteria in lower respiratory tract.

  2. Microbiome in induced sputum [ Time Frame: Baseline, 3 months ]
    Induced sputum represents the specimen from lower respiratory tract and should be processed within six hours after collection. Sputum plugs were separated from contaminating saliva by macroscopic examination using sterile forceps and weighed. Bacterial genomic DNA was isolated from sputum plugs of the same weight using the specific kits. The 16S bacterial ribosomal RNA genes were Polymerase Chain Reaction (PCR)-amplified with the appropriate controls against reagent contamination. Amplified DNA fragments were sequenced using the specific sequencing platform. Sequencing reads were processed and analyzed by the specific algorithm and software. The composition and diversity of microbiome are represented by major taxonomic groups at both phylum and genus levels. If necessary, Quantitative PCR for 16S rRNA gene will be performed to validate the results of sequencing. By using these methos, we can detect the microbiome's composition and its shift.

  3. Forced Expiratory Volume in 1 Second [ Time Frame: Baseline, 3 months, 15 months ]
    Change from baseline. Pulmonary function assessments were performed using centralized spirometry according to international standards. FEV1 was measured after 15 minutes of inhaling salbutamol 400ug.

  4. COPD Assessment Test(CAT) Score [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months, 15 months ]
    The COPD Assessment Test (CAT) is an 8-item uni-dimensional measure of health status impairment in COPD, containing 6 grades from 0 to 5.

  5. modified Medical Research Council(mMRC) scale [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months, 15 months ]
    The modified Medical Research Council scale is a simple and powerful tool to evaluate the breathlessness, containing 5 grades from 0 to 4.

  6. serum C-reactive protein(CRP) levels [ Time Frame: Baseline, 3 months ]
    Serum CRP level is a sensitive marker of the systemic inflammation.

  7. interleukin(IL)-6 in induced sputum [ Time Frame: Baseline, 3 months ]
    Induced sputum represents the specimen from lower respiratory tract. Sputum supernatant was batch analysed for the cytokines IL-6 using commercial highsensitivity sandwich ELISA kits. Inflammatory factors represent local inflammation levels in lower respiratory tract.

  8. IL-8 in induced sputum [ Time Frame: Baseline, 3 months ]
    Induced sputum represents the specimen from lower respiratory tract. Sputum supernatant was batch analysed for the cytokines IL-8 using commercial highsensitivity sandwich ELISA kits. Inflammatory factors represent local inflammation levels in lower respiratory tract.

  9. IL-1β in induced sputum [ Time Frame: Baseline, 3 months ]
    Induced sputum represents the specimen from lower respiratory tract. Sputum supernatant was batch analysed for the cytokines IL-1β using commercial highsensitivity sandwich ELISA kits. Inflammatory factors represent local inflammation levels in lower respiratory tract.

  10. Number of Patients With Adverse Events, Serious Adverse Events, and Death [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months, 15 months ]
    The overall rate of adverse events reported from initiation to the last time follow-up. Some laboratory examinations, such as blood routine, hepatorenal function and electrocardiogram, are performed twice separately at baseline and completion of intervention(3 months) in order to evaluate the safety of interventions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent must be obtained before any assessment is performed
  2. Male or female adults aged 18-65 years
  3. Diagnosed with COPD according to GOLD 2016 (The ratio of post-bronchodilator forced expiratory volume in 1 second (FEV1) to force vital capacity (FVC)<0.70 with the use of salbutamol 400ug)
  4. Moderate to very severe airflow limitation (post-bronchodilator FEV1 < 80% of the predicted normal value)
  5. A documented history of at least 2 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticoids and/or antibiotics, or at least 1 exacerbation in the previous 12 months that requires hospitalization.
  6. In the stable stage of COPD

Exclusion Criteria:

  1. Patients who have clinically significant and chronic hepatic, renal, cardiovascular and gastrointestinal abnormalities or malignant tumor (except for lung cancer) which could interfere with the assessment of the efficacy and safety of the study treatment
  2. Patients who are in critical conditions
  3. Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids or an acute exacerbation of any other diseases in the 4 weeks prior to screening
  4. Patients with concomitant pulmonary disease (including but not limited to bronchiectasis, interstitial lung disease, asthma)
  5. Patients who are highly likely to be lost during the 3-month treatment and the 1-year follow up
  6. Pregnant or nursing (lactating) women
  7. Patients who have been vaccinated against influenza in the current year, or against Streptococcus pneumoniae within five years, or have vaccination contraindications
  8. Patients who are allergic to amikacin or other aminoglycosides
  9. Patients who have participated in any interventional clinical trials in the three months prior to screening
  10. Patients with mental diseases or cognitive disorders which could interfere with treatment and follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03449459


Contacts
Contact: Jing Zhang, MD, PhD +86-13472782754 zhang.jing@zs-hospital.sh.cn

Locations
China, Guangdong
The First Affiliated Hospital of Guangzhou Medical University Not yet recruiting
Guangzhou, Guangdong, China
Contact: Bing Yuan, PhD    020-83205181    506638016@qq.com   
China, Shanghai
Ruijin Hospital, Shanghai Jiao Tong University Not yet recruiting
Shanghai, Shanghai, China
Contact: Ranran Dai, Master    021-34186000    drrcyy@msn.com   
Shanghai Zhongshan Hospital Not yet recruiting
Shanghai, Shanghai, China
Contact: Jing Zhang, MD,PhD    021-64041990    huxizhangjing@foxmail.com   
Contact: Jing Bi, Master    021-64041990    bi.jing@zs-hospital.sh.cn   
Sponsors and Collaborators
Shanghai Zhongshan Hospital
The First Affiliated Hospital of Guangzhou Medical University
Ruijin Hospital
Investigators
Principal Investigator: Jing Zhang, MD, PhD Shanghai Zhongshan Hospital

Responsible Party: Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier: NCT03449459     History of Changes
Other Study ID Numbers: B2017-197R
2017YFC1309303 ( Other Grant/Funding Number: Ministry of science and technology of China. )
First Posted: February 28, 2018    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Shanghai Zhongshan Hospital:
chronic obstructive pulmonary disease
aerosol inhaled amikacin
oral probiotics
combined influenza and pneumococcal vaccine inoculation
bacterial decolonization in lower respiratory tract

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Vaccines
Amikacin
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents